Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic
steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).
The "Global Non-Alcoholic
Steatohepatitis (NASH) Drugs Market: Insights, Trends and Forecast (2019-2028)" report has been added to ResearchAndMarkets.com's offering.
Based on its central metabolic role, targeting AMPK offers the opportunity to pursue a wide range of indications to treat chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic
steatohepatitis.
It is likely to decrease liver cell injury and also hepatic inflammation through resolution of
steatohepatitis. The partnership integrates Yuhan's expertise in FGF21 biology, obesity and NASH, with the pharmaceutical expertise and commitment of Boehringer Ingelheim to develop drugs for cardiometabolic diseases.
Present study was undertaken in 60 patients to assess the biochemical profile and various treatment modalities of patients with non-alcoholic
steatohepatitis. Out of which 28 (46.66%) were males and 32 (53.32%) were females.
The partnership has generated several early drug discovery targets shown to inhibit biological processes associated with inflammation and fibrosis that can lead to nonalcoholic
steatohepatitis (NASH), cirrhosis, and liver cancer.
Liver biopsy showed
steatohepatitis with bridging fibrosis (Figure 2).
Maryland Heights, MO, May 06, 2017 --(PR.com)-- Non-alcoholic
Steatohepatitis or Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic
steatohepatitis (NASH) and irreversible liver damage (cirrhosis).
A multimodal research process has provided clues to the role of angiogenesis in the etiology of nonalcoholic fatty liver disease (NAFLD) and its more serious cousin, nonalcoholic
steatohepatitis (NASH).
Long-term pioglitazone is not only safe for patients with non-alcoholic
steatohepatitis and prediabetes or type 2 diabetes but may be associated with significant improvements in fatty liver disease outcomes, compared with placebo, a study showed.